|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our previous study suggested that the overexpression of CD97 in cervical cancer was correlated with the aggressiveness of the tumour and that CD97 might be an independent poor prognostic factor for cervical cancer patients.
|
30883974 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD97 Promotes Tumor Aggressiveness Through the Traditional G Protein-Coupled Receptor-Mediated Signaling in Hepatocellular Carcinoma.
|
29704239 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings support targeted blockade of tumor CD97 as an approach to ameliorate metastatic spread.
|
29669286 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
E2F2 and EMR2 are preferentially expressed in adenocarcinomas subtypes versus other tumour types (squamous and others).
|
29072692 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The markers significantly overexpressed already in earlier tumor stages (pT1-2) of both histological subtypes (n = 19) have been clustered in a "diagnostic signature": PLA2G7, PRAME, MMP1, MMP3, MMP12, LIlRB2, TREM2, CHST2, IGFBP2, IGFBP7, KCNJ8, EMILIN2, CTHRC1, EMR2, WDR72, LPCAT1, COL4A2, CCL4, and SNX10.
|
26631031 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD97 is a tumor-associated adhesion-class G-protein-coupled receptor involved in modulating cell migration.
|
25174588 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Prometastatic GPCR CD97 is a direct target of tumor suppressor microRNA-126.
|
24274104 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All tumors were strongly CD97-positive, independent of the underlying histological subtype, suggesting high sensitivity of CD97 for this tumor.
|
24949957 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This phenotype may explain the discrepancy in survival between high and low CD97-expressing tumors.
|
23658650 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of transgenic CD97 in thyroid epithelium led to elevated ERK phosphorylation and increased numbers of Ki67+ cells in developing tumors.
|
22797060 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast, EMR2 nuclear expression correlated negatively with higher tumour grade.
|
21174063 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Based on an analysis showing earlier mortality among glioblastoma patients whose tumors highly express EMR2, we studied its expression patterns in glioblastoma and potential to mediate cellular proliferation and invasion.
|
21503828 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The study further lightened the tumor promoting role of CD97 small isoform in cancer progression and indicated the possible suppressive properties of the full length isoform of CD97.
|
20428763 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We show here that CD97alpha promotes angiogenesis in vivo as demonstrated with purified protein in a directed in vivo angiogenesis assay (DIVAA) and by enhanced vascularization of developing tumors expressing CD97.
|
15576472 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
There was strong correlation between the distribution patterns of CD97(stalk) and CD55 on tumor tissues (r=0.73, P<0.05).
|
16130195 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunoprecipitation of CD97 from the Colo 205 tumor cell line revealed the established 78 and 83 kDa products, while a 52 and 57 kDa band were obtained from smooth muscle cells.
|
15386373 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast to CD97, which is found in most colorectal adenocarcinomas, only 8 of 81 of these tumors expressed EMR2.
|
12761622 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, intralobular and interlobular pancreatic ducts were CD97+.All tumors were EMR2-.
|
12428789 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD97 was absent or only weakly present in patients with postoperative T1 tumors but increased greatly with the progression to postoperative T4 tumors.
|
9135025 |
1997 |